{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "9e456858-255a-49d2-8afe-6cae0570d043",
   "metadata": {},
   "source": [
    "# üß™ 100 Topics for ChEMBL_35 in Drug Discovery and Development\n",
    "### üìò Bilingual Table | B·∫£ng song ng·ªØ\n",
    "\n",
    "| No. | English Topic | Ch·ªß ƒë·ªÅ ti·∫øng Vi·ªát |\n",
    "|-----|----------------|-------------------|\n",
    "| 1 | QSAR model building from ChEMBL IC50 data | X√¢y d·ª±ng m√¥ h√¨nh QSAR t·ª´ d·ªØ li·ªáu IC50 trong ChEMBL |\n",
    "| 2 | Predicting bioactivity from molecular descriptors | D·ª± ƒëo√°n ho·∫°t t√≠nh sinh h·ªçc t·ª´ c√°c ƒë·∫∑c tr∆∞ng ph√¢n t·ª≠ |\n",
    "| 3 | Extracting lead-like compounds | Tr√≠ch xu·∫•t c√°c h·ª£p ch·∫•t gi·ªëng lead |\n",
    "| 4 | Filtering rule-of-five compliant molecules | L·ªçc c√°c ph√¢n t·ª≠ tu√¢n th·ªß quy t·∫Øc Lipinski |\n",
    "| 5 | Analyzing drug-likeness using RDKit | Ph√¢n t√≠ch t√≠nh gi·ªëng thu·ªëc b·∫±ng RDKit |\n",
    "| 6 | Virtual screening based on ChEMBL targets | S√†ng l·ªçc ·∫£o d·ª±a tr√™n c√°c target trong ChEMBL |\n",
    "| 7 | Ligand-based drug design using ChEMBL | Thi·∫øt k·∫ø thu·ªëc d·ª±a tr√™n ligand t·ª´ ChEMBL |\n",
    "| 8 | Structure-Activity Relationship (SAR) mining | Khai th√°c m·ªëi quan h·ªá c·∫•u tr√∫c ‚Äì ho·∫°t t√≠nh (SAR) |\n",
    "| 9 | Tanimoto similarity search using ChEMBL + RDKit | T√¨m ki·∫øm t∆∞∆°ng ƒë·ªìng Tanimoto v·ªõi ChEMBL v√† RDKit |\n",
    "| 10 | Chemical space mapping of ChEMBL molecules | B·∫£n ƒë·ªì kh√¥ng gian h√≥a h·ªçc c·ªßa c√°c ph√¢n t·ª≠ ChEMBL |\n",
    "| 11 | Predicting LogP and TPSA of ChEMBL compounds | D·ª± ƒëo√°n LogP v√† TPSA c·ªßa c√°c h·ª£p ch·∫•t ChEMBL |\n",
    "| 12 | Screening for CNS-active drugs | S√†ng l·ªçc thu·ªëc t√°c ƒë·ªông h·ªá th·∫ßn kinh trung ∆∞∆°ng |\n",
    "| 13 | Scaffold hopping analysis | Ph√¢n t√≠ch thay ƒë·ªïi khung h√≥a h·ªçc (scaffold hopping) |\n",
    "| 14 | Prioritizing compounds for synthesis | ∆Øu ti√™n h·ª£p ch·∫•t cho qu√° tr√¨nh t·ªïng h·ª£p |\n",
    "| 15 | Designing focused libraries from ChEMBL | Thi·∫øt k·∫ø th∆∞ vi·ªán h√≥a h·ªçc t·∫≠p trung t·ª´ ChEMBL |\n",
    "| 16 | Finding natural product-like molecules | T√¨m c√°c ph√¢n t·ª≠ gi·ªëng s·∫£n ph·∫©m t·ª± nhi√™n |\n",
    "| 17 | Mining kinase inhibitors from ChEMBL | Khai th√°c ch·∫•t ·ª©c ch·∫ø kinase t·ª´ ChEMBL |\n",
    "| 18 | Target prediction for orphan molecules | D·ª± ƒëo√°n m·ª•c ti√™u cho c√°c ph√¢n t·ª≠ kh√¥ng r√µ target |\n",
    "| 19 | Linking ChEMBL with DrugBank for repurposing | K·∫øt n·ªëi ChEMBL v·ªõi DrugBank ƒë·ªÉ t√°i ƒë·ªãnh h∆∞·ªõng thu·ªëc |\n",
    "| 20 | Comparing ChEMBL scaffolds with FDA drugs | So s√°nh khung h√≥a h·ªçc ChEMBL v·ªõi thu·ªëc FDA |\n",
    "| 21 | Top 50 protein targets by activity count | 50 protein m·ª•c ti√™u c√≥ nhi·ªÅu ho·∫°t t√≠nh nh·∫•t |\n",
    "| 22 | Analyzing GPCR-targeted ligands | Ph√¢n t√≠ch ligand nh·∫Øm GPCR |\n",
    "| 23 | Extracting kinase-binding molecules | Tr√≠ch xu·∫•t h·ª£p ch·∫•t g·∫Øn kinase |\n",
    "| 24 | Target class distribution in ChEMBL | Ph√¢n b·ªë c√°c nh√≥m target trong ChEMBL |\n",
    "| 25 | Multi-target ligand profiling | L·∫≠p h·ªì s∆° ligand ƒëa ƒë√≠ch |\n",
    "| 26 | Correlating bioactivity with target taxonomy | Li√™n h·ªá ho·∫°t t√≠nh v·ªõi ph√¢n lo·∫°i target |\n",
    "| 27 | Disease association of ChEMBL targets | M·ªëi li√™n h·ªá gi·ªØa target v√† b·ªánh h·ªçc |\n",
    "| 28 | Ortholog mapping of targets (human ‚Üí mouse) | √Ånh x·∫° protein gi·ªØa ng∆∞·ªùi v√† chu·ªôt |\n",
    "| 29 | Target pathway analysis via UniProt/KEGG | Ph√¢n t√≠ch pathway c·ªßa target b·∫±ng UniProt/KEGG |\n",
    "| 30 | Binding site comparison across targets | So s√°nh v·ªã tr√≠ g·∫Øn ligand gi·ªØa c√°c target |\n",
    "| 31 | 3D target structure availability from PDB | Kh·∫£ nƒÉng truy xu·∫•t c·∫•u tr√∫c 3D c·ªßa target t·ª´ PDB |\n",
    "| 32 | Predicting binding modes via molecular docking | D·ª± ƒëo√°n c√°ch th·ª©c g·∫Øn ligand b·∫±ng docking |\n",
    "| 33 | Sequence similarity clustering of targets | Ph√¢n nh√≥m target theo t∆∞∆°ng ƒë·ªìng chu·ªói |\n",
    "| 34 | Heatmap of target-ligand interaction count | Bi·ªÉu ƒë·ªì nhi·ªát v·ªÅ s·ªë l∆∞·ª£ng ligand t∆∞∆°ng t√°c target |\n",
    "| 35 | ChEMBL target network visualization | Tr·ª±c quan h√≥a m·∫°ng l∆∞·ªõi target |\n",
    "| 36 | Target enrichment from gene sets | L√†m gi√†u target t·ª´ b·ªô gene |\n",
    "| 37 | Mining antimicrobial targets in ChEMBL | Khai th√°c target kh√°ng khu·∫©n t·ª´ ChEMBL |\n",
    "| 38 | Visualization of protein families | Tr·ª±c quan h√≥a h·ªç protein t·ª´ ChEMBL |\n",
    "| 39 | Finding targets with dual antagonist/agonist activity | T√¨m target c√≥ ho·∫°t t√≠nh ƒë·ªëi kh√°ng v√† ƒë·ªìng v·∫≠n |\n",
    "| 40 | Top viral/bacterial targets in ChEMBL | C√°c target virus/vi khu·∫©n ph·ªï bi·∫øn nh·∫•t |\n",
    "| 41 | Linking ChEMBL drugs to clinical phases | Li√™n k·∫øt d·ªØ li·ªáu thu·ªëc v·ªõi c√°c pha l√¢m s√†ng |\n",
    "| 42 | Drugs with most activity data | Thu·ªëc c√≥ nhi·ªÅu d·ªØ li·ªáu ho·∫°t t√≠nh nh·∫•t |\n",
    "| 43 | Predicting clinical success from early bioactivity | D·ª± ƒëo√°n kh·∫£ nƒÉng th√†nh c√¥ng l√¢m s√†ng |\n",
    "| 44 | Time-to-market estimation using ChEMBL history | ∆Ø·ªõc l∆∞·ª£ng th·ªùi gian ra th·ªã tr∆∞·ªùng t·ª´ ChEMBL |\n",
    "| 45 | Mapping ChEMBL drugs to WHO ATC codes | √Ånh x·∫° thu·ªëc ChEMBL sang m√£ ATC c·ªßa WHO |\n",
    "| 46 | Drug repurposing candidates from ChEMBL | C√°c thu·ªëc ti·ªÅm nƒÉng t√°i ƒë·ªãnh h∆∞·ªõng |\n",
    "| 47 | Comparing clinical vs. preclinical molecules | So s√°nh thu·ªëc l√¢m s√†ng v√† ti·ªÅn l√¢m s√†ng |\n",
    "| 48 | Linking ChEMBL with clinicaltrials.gov | Li√™n k·∫øt ChEMBL v·ªõi d·ªØ li·ªáu th·ª≠ nghi·ªám l√¢m s√†ng |\n",
    "| 49 | FDA-approved ChEMBL drugs analysis | Ph√¢n t√≠ch thu·ªëc ChEMBL ƒë√£ ƒë∆∞·ª£c FDA ph√™ duy·ªát |\n",
    "| 50 | Trends in target class approval | Xu h∆∞·ªõng ph√™ duy·ªát theo nh√≥m target |\n",
    "| 51 | Withdrawn drugs and their ChEMBL profiles | H·ªì s∆° thu·ªëc b·ªã r√∫t kh·ªèi th·ªã tr∆∞·ªùng |\n",
    "| 52 | Oncology-focused drug trend in ChEMBL | Xu h∆∞·ªõng thu·ªëc ung th∆∞ trong ChEMBL |\n",
    "| 53 | Antiviral compounds mapping to COVID-19 targets | Ph√¢n t·ª≠ kh√°ng virus t∆∞∆°ng ·ª©ng v·ªõi ƒë√≠ch COVID-19 |\n",
    "| 54 | Neuropsychiatric drug insights from ChEMBL | Ph√¢n t√≠ch thu·ªëc th·∫ßn kinh ‚Äì t√¢m th·∫ßn |\n",
    "| 55 | Drug safety flags and bioactivity profile | C·∫£nh b√°o an to√†n li√™n k·∫øt v·ªõi ho·∫°t t√≠nh sinh h·ªçc |\n",
    "| 56 | Comparing ChEMBL drugs with WHO Essential Medicines | So s√°nh ChEMBL v·ªõi danh m·ª•c thu·ªëc thi·∫øt y·∫øu WHO |\n",
    "| 57 | Pharmacovigilance risk signals in ChEMBL | D·ªØ li·ªáu t√≠n hi·ªáu c·∫£nh b√°o d∆∞·ª£c l√Ω |\n",
    "| 58 | Pediatric drug insights from ChEMBL | Ph√¢n t√≠ch thu·ªëc d√†nh cho tr·∫ª em |\n",
    "| 59 | Orphan drug discovery via ChEMBL | Kh√°m ph√° thu·ªëc hi·∫øm t·ª´ ChEMBL |\n",
    "| 60 | ChEMBL ‚Üí Real-world evidence mapping | Li√™n k·∫øt d·ªØ li·ªáu ChEMBL v·ªõi d·ªØ li·ªáu th·ª±c t·∫ø |\n",
    "| 61 | QSAR with Random Forest and ChEMBL descriptors | QSAR v·ªõi Random Forest v√† ƒë·∫∑c tr∆∞ng t·ª´ ChEMBL |\n",
    "| 62 | Deep learning models for activity prediction | M√¥ h√¨nh h·ªçc s√¢u ƒë·ªÉ d·ª± ƒëo√°n ho·∫°t t√≠nh |\n",
    "| 63 | XGBoost optimization for IC50 prediction | T·ªëi ∆∞u h√≥a XGBoost ƒë·ªÉ d·ª± ƒëo√°n IC50 |\n",
    "| 64 | AutoML pipelines for ChEMBL data | D√≤ng AutoML cho d·ªØ li·ªáu ChEMBL |\n",
    "| 65 | Feature selection in ChEMBL-based models | Ch·ªçn ƒë·∫∑c tr∆∞ng trong m√¥ h√¨nh t·ª´ ChEMBL |\n",
    "| 66 | Hyperparameter tuning with Optuna for drug models | Tinh ch·ªânh si√™u tham s·ªë b·∫±ng Optuna cho m√¥ h√¨nh thu·ªëc |\n",
    "| 67 | Evaluating overfitting in QSAR models | ƒê√°nh gi√° overfitting trong m√¥ h√¨nh QSAR |\n",
    "| 68 | Unsupervised clustering of ChEMBL compounds | Ph√¢n c·ª•m kh√¥ng gi√°m s√°t c√°c h·ª£p ch·∫•t ChEMBL |\n",
    "| 69 | Dimensionality reduction for chemical descriptors | Gi·∫£m chi·ªÅu d·ªØ li·ªáu cho ƒë·∫∑c tr∆∞ng h√≥a h·ªçc |\n",
    "| 70 | Predicting drug-target interactions using ML | D·ª± ƒëo√°n t∆∞∆°ng t√°c thu·ªëc‚Äìƒë√≠ch b·∫±ng h·ªçc m√°y |\n",
    "| 71 | Streamlit dashboard for bioactivity exploration | Dashboard Streamlit ƒë·ªÉ kh√°m ph√° ho·∫°t t√≠nh sinh h·ªçc |\n",
    "| 72 | Plotting IC50 distribution across targets | V·∫Ω ph√¢n b·ªë IC50 tr√™n c√°c ƒë√≠ch t√°c d·ª•ng |\n",
    "| 73 | Interactive similarity search app | ·ª®ng d·ª•ng t√¨m ki·∫øm t∆∞∆°ng ƒë·ªìng t∆∞∆°ng t√°c |\n",
    "| 74 | 3D plotting of molecular chemical space | V·∫Ω 3D kh√¥ng gian h√≥a h·ªçc ph√¢n t·ª≠ |\n",
    "| 75 | Comparative barplots for molecule classes | Bi·ªÉu ƒë·ªì so s√°nh c√°c l·ªõp h·ª£p ch·∫•t |\n",
    "| 76 | Target-ligand network graph using NetworkX | ƒê·ªì th·ªã m·∫°ng l∆∞·ªõi target-ligand b·∫±ng NetworkX |\n",
    "| 77 | Correlation heatmap of physicochemical properties | Bi·ªÉu ƒë·ªì nhi·ªát t∆∞∆°ng quan c√°c t√≠nh ch·∫•t l√Ω h√≥a |\n",
    "| 78 | Violin plot for multi-target activity spectrum | Bi·ªÉu ƒë·ªì violin cho ph·ªï ho·∫°t t√≠nh ƒëa ƒë√≠ch |\n",
    "| 79 | Radar chart of drug-likeness scores | Bi·ªÉu ƒë·ªì radar c·ªßa c√°c ƒëi·ªÉm gi·ªëng thu·ªëc |\n",
    "| 80 | Timeline of drug approval dates | D√≤ng th·ªùi gian v·ªÅ ng√†y ph√™ duy·ªát thu·ªëc |\n",
    "| 81 | Linking ChEMBL with UniProt for protein info | Li√™n k·∫øt ChEMBL v·ªõi UniProt ƒë·ªÉ tra protein |\n",
    "| 82 | Merging ChEMBL with PubChem CID data | G·ªôp d·ªØ li·ªáu ChEMBL v·ªõi CID t·ª´ PubChem |\n",
    "| 83 | DrugBank interaction cross-validation | Ki·ªÉm ch·ª©ng ch√©o t∆∞∆°ng t√°c v·ªõi DrugBank |\n",
    "| 84 | Linking ChEMBL to FDA label data | Li√™n k·∫øt ChEMBL v·ªõi d·ªØ li·ªáu nh√£n FDA |\n",
    "| 85 | Annotating ChEMBL targets with PDB structures | Ch√∫ th√≠ch target ChEMBL b·∫±ng c·∫•u tr√∫c PDB |\n",
    "| 86 | Integrating adverse event data (SIDER/FAERS) | T√≠ch h·ª£p d·ªØ li·ªáu t√°c d·ª•ng ph·ª• (SIDER/FAERS) |\n",
    "| 87 | Gene‚Äìcompound mapping with bioactivity overlays | √Ånh x·∫° gene ‚Äì h·ª£p ch·∫•t v·ªõi l·ªõp ph·ªß ho·∫°t t√≠nh |\n",
    "| 88 | ChEMBL + BindingDB similarity validation | So s√°nh t∆∞∆°ng ƒë·ªìng gi·ªØa ChEMBL v√† BindingDB |\n",
    "| 89 | Converting ChEMBL SMILES to InChIKeys | Chuy·ªÉn SMILES t·ª´ ChEMBL th√†nh InChIKey |\n",
    "| 90 | Merging ChEMBL with chemical vendor data | G·ªôp ChEMBL v·ªõi d·ªØ li·ªáu nh√† cung c·∫•p h√≥a ch·∫•t |\n",
    "| 91 | Case study: JAK inhibitors from ChEMBL | Ca l√¢m s√†ng: ch·∫•t ·ª©c ch·∫ø JAK t·ª´ ChEMBL |\n",
    "| 92 | Finding selective COX-2 inhibitors | T√¨m c√°c ch·∫•t ·ª©c ch·∫ø COX-2 ch·ªçn l·ªçc |\n",
    "| 93 | Comparative analysis of antihypertensive agents | Ph√¢n t√≠ch so s√°nh thu·ªëc h·∫° huy·∫øt √°p |\n",
    "| 94 | Mechanism-of-action clustering of ChEMBL drugs | Ph√¢n nh√≥m theo c∆° ch·∫ø t√°c d·ª•ng c·ªßa thu·ªëc ChEMBL |\n",
    "| 95 | Extracting structure alerts for toxicity | Tr√≠ch xu·∫•t t√≠n hi·ªáu c·∫•u tr√∫c g√¢y ƒë·ªôc |\n",
    "| 96 | Multi-task learning for pan-target inhibition | H·ªçc ƒëa nhi·ªám cho ·ª©c ch·∫ø to√†n ƒë√≠ch |\n",
    "| 97 | Matched molecular pair analysis from ChEMBL | Ph√¢n t√≠ch c·∫∑p ph√¢n t·ª≠ gi·ªëng nhau t·ª´ ChEMBL |\n",
    "| 98 | Drug synergy potential prediction using ChEMBL | D·ª± ƒëo√°n ti·ªÅm nƒÉng hi·ªáp ƒë·ªìng thu·ªëc t·ª´ ChEMBL |\n",
    "| 99 | Epigenetic modulator screening via ChEMBL | S√†ng l·ªçc ch·∫•t ƒëi·ªÅu bi·∫øn epigenetic qua ChEMBL |\n",
    "| 100 | Rare disease drug lead identification | T√¨m ki·∫øm h·ª£p ch·∫•t lead cho b·ªánh hi·∫øm g·∫∑p |"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f55bda58-d4fb-4df7-a7f2-b3639a48cc4d",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
